Turkish Journal of Gastroenterology
Poster

Evaluation of rheumatologists’ awareness of hepatitis B reactivation before immunosuppressive treatment

1.

University of Health Sciences, Konya Education and Research Hospital

2.

Sakarya University Faculty of Medicine, Education and Research Hospital, Department of Rheumatology

3.

Sakarya University Faculty of Medicine, Education and Research Hospital, Department of Gastroenterology

4.

Sakarya University Faculty of Medicine, Education and Research Hospital, Department of Infectious Diseases

Turk J Gastroenterol 2019; 30: Supplement 25-25
DOI: 10.5152/tjg.2019.14
Read: 1088 Downloads: 161 Published: 25 July 2019

Abstract

 

INTRODUCTION: HBV reactivation (HBVr) is a well-known complication in patients receiving immunosuppressive therapy and leads to significant morbidity and mortality. As the use of biological agents becomes more common in rheumatology practice, a growing number of HBVr cases are reported. The aim of this study was to evaluate the awareness of rheumatologists about the risk of HBVR, pre-treatment screening and prophylactic treatment in patients receiving immunosuppressive therapy.The aim of our study was to evaluate the awareness of rheumatologists about the risk of HBVR, pre-treatment screening and prophylactic treatment in patients receiving immunosuppressive therapy.

METHODS: All rheumatyology specialist members of the Turkish Association of Rheumatology were invited to the study between April 1 and June 30, 2018. An e-mail was sent to the participants 3 times once in a month with an informative message, with a link to the questionnaire that allows the survey to be completed only once. Inclusion criteria were to be a member of Turkish Rheumatology Association and to be a rheumatology specialist as an active clinician in Turkey. The results of the survey were evaluated by the researchers.

SONUÇLAR: A questionnaire was sent to 270 rheumatologists who met the criteria, 48 (%17,8) questionnaires were completed and included in the study. Participants had an average of 6.5 (1-25) years of professional experience. 93.8% (45/48) of the rheumatologists thought that all patients should be screened for HBV before immunosuppressive treatment and 6.2% thought that HBV screening should be performed only in high-risk patients. In patients with high-risk immunosuppressive therapy, such as Rituximab screening rate for HBV was %95,8 (46/48) but in patients with low risk such as less than 10 mg of prednisolone and their equivalent for more than 4 weeks screening rate was %35,4(17/48). When selecting an initial screening test; all of the rheumatologists (48/48) checked the HBsAg and %83,3 (40/48) would checked also HBcIgG and antiHBs. 44 (91.7%) rheumatologists stated that he or she had at least one patient with prophylaxis. Tenofovir (84.1%) was most commonly used drug in prophylaxis. 14 (29.2%) rheumatologists stated that HBVr was detected in at least one patient and 11of them stated that they had patients whose rheumatologic therapies were interrupted because of HBVr. 

TARTIŞMA ve SONUÇ: The results of our study show that the awareness of rheumatologists about HBV reactivation is relatively high but there is a need to further improvement.

Files
EISSN 2148-5607